NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, appointed Luke Oh, President. In his new role, Oh will spearhead NIT’s local team from its Rockville headquarters. His primary focus will be on accelerating the clinical development of NT-I7, NeoImmuneTech’s long-acting human IL-7, and strategizing the regulatory path for its potential inaugural approval for the treatment of Acute Radiation Syndrome (ARS). Oh brings expertise in regulatory policies and...